NCCN指南®见解:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤,版本2.2026
William G Wierda1, Jennifer Brown2, Jeremy S Abramson3
11The University of Texas MD Anderson Cancer Center.
Journal of the National Comprehensive Cancer Network : JNCCN
|March 13, 2026
概括
新的治疗方法,如布鲁顿氨酸激酶抑制剂 (BTKis) 和BCL2抑制剂 (BCL2i),可以改善慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 的存活率. 现在的指导方针包括对CLL/SLL和里希特转换的更新,包括新的治疗方法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床指南 临床指南
背景情况:
- 布鲁顿氨酸激酶抑制剂 (BTKis) 和BCL2抑制剂 (BCL2i) 改善了慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 的存活率.
- 与BTKi单疗法或化学免疫疗法 (CIT) 相比,时间有限的BCL2i疗法显示出更高的不可检测的可测量的残留疾病 (uMRD) 率.
- 皮尔托布鲁丁尼和利索卡巴丁基马拉莱塞尔是BTKi和BCL2i治疗后复发性/耐药性疾病的先进选择.
研究的目的:
- 突出了NCCN关于治疗CLL/SLL的指导方针的重大更新.
- 为了解决里希特转换的管理,CLL/SLL的预后不佳的并发症.
- 将新的治疗选择纳入治疗指南.
主要方法:
- 随机临床试验和最近的治疗进展的综述.
- 对治疗结果的分析,包括不可检测的可测量的残留疾病 (uMRD) 的比例.
- 考虑在里希特转换中的克隆关系的分子分析.
主要成果:
- 含BCL2i的疗法比BTKi单疗或CIT更高的UMRD率.
- 皮尔托布鲁丁尼和利索卡巴丁基马拉莱塞尔是复发或耐药性疾病患者的新兴选择.
- 分子分析有助于选择CLL/SLL和里希特转换的最佳治疗方法.
结论:
- NCCN指南洞察力为CLL/SLL和里赫特转换管理提供了关键的更新.
- 新型药物如皮尔托布鲁丁尼和利索卡巴丁基马拉莱克尔被整合到不断发展的治疗范式中.
- 以分子数据为基础的个性化治疗选择是改善患者治疗结果的关键.
相关概念视频
Lymphoid Cells and Tissues
3.7K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.7K
Primary Lymphoid Organs
16.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.4K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Secondary Lymphoid Organs
10.0K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
10.0K
Treatment Resistent Cancers
1.5K
1.5K
Nephrotic Syndrome II : Assessment and Medical Management
294
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
294


